{"id":"W3030566019","doi":"10.1200/jco.2020.38.15_suppl.6002","title":"Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Hazard ratio; Oncology; Placebo; Ovarian cancer; Clinical endpoint; PARP inhibitor; Progression-free survival; BRCA mutation; Chemotherapy; Cancer; Confidence interval; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002174399,0.0002401207,0.00185658,0.0001176534,0.00006949923,0.0000352644,0.0001205961,0.0004169926,0.0001030825],"category_scores_gemma":[0.004813588,0.0001819501,0.0002132666,0.0002373925,0.0002951752,0.0003384654,0.00004071842,0.001690411,0.000003885231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000375519,"about_ca_system_score_gemma":0.002429107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002750766,"about_ca_topic_score_gemma":0.0002056242,"domain_scores_codex":[0.9946778,0.0007967144,0.003119949,0.0004649099,0.0006094429,0.0003311861],"domain_scores_gemma":[0.99232,0.003448518,0.002904262,0.0001690337,0.000656592,0.0005016119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.914829,0.002762318,0.0177792,0.00002021919,0.0005463613,0.002026281,0.001885189,0.0001803694,0.0003096104,0.00005838088,0.004639241,0.05496379],"study_design_scores_gemma":[0.7955555,0.02487744,0.1699225,0.0006186906,0.0002853032,0.00006459017,0.0002965262,0.001672604,0.00009463966,0.0002149098,0.006168873,0.0002283714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783008,0.00006731637,0.001266245,0.01750666,0.00128582,0.000547661,0.0001152509,0.0000160261,0.0008942799],"genre_scores_gemma":[0.9851008,0.0001903684,0.005525118,0.006854811,0.002195467,0.00001224076,0.00004090981,0.00002945293,0.00005083951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1521433,"threshold_uncertainty_score":0.7419711,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1582817161038081,"score_gpt":0.4573256149871514,"score_spread":0.2990438988833433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}